Hangzhou Minsheng Healthcare Co., Ltd. Class A

Hangzhou Minsheng Healthcare Co., Ltd. Class A

SSZSE:301507
11.22
CNY
-0.12
(-1.06%)
0.26EPS
53.70P/E
4.78BMarket Cap
Apr 29Next Earn
2018 Y
2019 Y
2020 Y
2021 Y
2022 Y
2023 Y
2024 Y
2025 Y
TTM
Revenue per Share
1.16
1.31
1.23
1.88
2.08
1.97
1.82
2.17
2.54
Basic EPS, GAAP
0.12
0.16
0.14
0.27
0.3
0.29
0.26
0.33
0.25
Free Cash Flow per Basic Share
0.29
0.25
0.23
0.07
0.26
0.24
0.04
-0.05
- -
Dividend per Share
0.01
0.01
0.01
0.58
- -
- -
0.1
0.1
- -
Book Value per Share
1.08
1.24
1.67
1.93
2.22
4.13
4.29
4.48
4.54
Tangible Book Value per Share
0.91
1.09
1.53
1.79
2.09
4.02
4.19
4.05
4.12
Basic Weighted Avg Shares
267
267
357
260
263
295
353
360
355
Sales/Revenue/Turnover
311
350
439
490
547
582
641
782
903
Operating Margin (%)
15.01
17.91
15.3
13.97
15.41
15.44
13.16
11.76
11.48
Depreciation Expense
29
29
29
31
32
28
23
29
- -
Net Income, GAAP
33
44
51
70
79
86
92
119
89
Effective Tax Rate (%)
21.29
25.51
18.75
11.04
10.29
11.53
13.57
11.95
9.73
Profit Margin (%)
10.71
12.47
11.54
14.34
14.44
14.72
14.32
15.2
9.82
Working Capital
-7
55
191
263
137
997
1,051
950
697
LT Debt
- -
- -
3
3
2
1
- -
1
1
Total Equity
288
332
447
515
594
1,473
1,531
1,718
1,740
Return on Invested Capital (%)
- -
12.74
12.06
14.32
14.32
8.43
6.14
7.4
- -
Return on Capital (%)
- -
15.37
14.4
14.41
14.21
8.27
6.11
7.17
- -
Return on Common Equity (%)
- -
14.08
13.03
14.6
14.25
8.29
6.11
7.59
- -

Capital Structure

CNY

•

in mil. unless spec.
Mar'26
Jun'26
Sep'26
ST Debt
2
2
2
LT Borrowings
- -
- -
- -
LT Finance Leases
2
1
1
Preferred Equity and Hybrid Capital
- -
- -
- -
Shares Outstanding
357
357
357
Market Capitalization
4,995
4,289
4,785

Working Capital

CNY

•

in mil. unless spec.
Mar'26
Jun'26
Sep'26
Total Current Assets
1,109
1,034
1,017
Cash, Cash Equivalents & STI
848
809
683
Accounts Receivable, Net
56
57
34
Inventories
65
68
75
Total Current Liabilities
289
339
320
Payables & Accruals
- -
- -
- -
ST Debt
2
2
2
Deferred Revenue
- -
- -
- -

Growth Rates

CNY

•

in mil. unless spec.

(avg. rate of change)

10 years
5 years
1 year
Total Equity
- -
38.96%
12.26%
Free Cash Flow
- -
-25.94%
-241.17%
Net Income, GAAP
- -
19.19%
29.35%
Sales/Revenue/Turnover
- -
12.32%
21.89%
Total Cash Common Dividend
- -
- -
-0.3%

Quarterly Revenue

CNY

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
235
163
122
121
641
2025
271
191
- -
159
782
2026
317
218
208
- -
- -

Quarterly Earnings Per Share

CNY

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
0.17
0.05
0.02
0.02
0.26
2025
0.18
0.06
- -
0.01
0.33
2026
0.18
0.06
- -
- -
- -

Quarterly Dividends Per Share

CNY

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
- -
- -
- -
- -
0.1
2025
- -
- -
- -
- -
0.1
2026
- -
- -
- -
- -
- -

Company Description

CEO
Hai Jun Zhang
Full Time Employees
727
Sector
Health technology
Industry
Pharmaceuticals: other
Address
Hangzhou China
IPO Date
Sep 5, 2023
Website
21vita.com
Business
Hangzhou Minsheng Healthcare Co., Ltd. is a China-based pharmaceutical and healthcare company primarily engaged in the research, development, manufacturing, and commercialization of over-the-counter (OTC) medicines, dietary supplements, vitamins and minerals, probiotics, and functional foods. A subsidiary of Hangzhou Minsheng Pharmaceutical Holding Group, the company organizes its operations across four primary brand pillars: 21 Super-Vita (21金维他), offering multivitamin and multimineral tablets, calcium supplements, zinc formulations, vitamin C, and effervescent nutrition products; Probi (普瑞宝), offering specialized probiotic powders, gut health capsules, synbiotics, and microecological health supplements; Minsheng (民生), producing therapeutic OTC pharmaceuticals such as hydrotalcite gastrointestinal suspensions, topical dermatological formulations, and ophthalmic preparations, alongside medical aesthetic products; and Minsheng Tongchun (民生同春), marketing traditional and trendy wellness formulations, functional herbal teas, sports nutrition, and workplace wellness products. The company distributes its offerings nationwide across the People's Republic of China through retail pharmacy chains, commercial distributors, hospitals, and major e-commerce platforms. In recent developments, the company listed its Class A shares on the Shenzhen Stock Exchange ChiNext board in September 2023. To accelerate upstream integration in microecological nutrition, the company completed the strategic acquisition of probiotic strain specialist Minsheng Zhongke Jiayi (Shandong), gaining proprietary microbial cultivation and microencapsulation capabilities. Additionally, the company reintroduced the heritage brand Minsheng Tongchun to target youth and lifestyle wellness segments, secured new domestic pharmaceutical registrations including novel hydrotalcite liquid formulations, and expanded strategic research into gut-brain axis health, metabolic support, and sleep management. Founded in 2009, Hangzhou Minsheng Healthcare Co., Ltd. is headquartered in Hangzhou, Zhejiang Province, China.